MADRIGAL PHARMACEUTICALS, INC. (MDGL) Return on equity 2017–2025
MADRIGAL PHARMACEUTICALS, INC. (MDGL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-47.8%FY2025 · since FY2017: -17.1% → -47.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -47.8% | +13.9 pp |
| FY2024 | -61.8% | +30.4 pp |
| FY2023 | -92.2% | +57.4 pp |
| FY2022 | -149.6% | -26.3 pp |
| FY2021 | -123.3% | -39.0 pp |
| FY2020 | -84.3% | -64.1 pp |
| FY2019 | -20.2% | -13.3 pp |
| FY2018 | -6.9% | +10.2 pp |
| FY2017 | -17.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MDGL financial trends
MDGL RevenueMDGL Net incomeMDGL Net marginMDGL Gross profitMDGL Gross marginMDGL Operating incomeMDGL Operating marginMDGL Operating cash flowMDGL Free cash flowMDGL Capital expendituresMDGL Stock buybacksMDGL Dividends paidMDGL Total assetsMDGL Total liabilitiesMDGL Shareholders’ equityMDGL overview →